With the new Ras G-LISA™ kit you can now measure Ras activation from cell and tissue samples in less than 3 h. G-LISA™ requires only 1-5% of the material needed for a conventional pull-down assay. You will also be able to handle large sample numbers and generate quantitative results. For a more detailed introduction on G-LISA™ assays and a listing of other available G-LISA™ kits, see our main G-LISA™ page.
The Ras G-LISA™ kit contains a Ras GTP-binding protein linked to the wells of a 96 well plate. Active, GTP-bound Ras in cell/tissue lysates will bind to the wells while inactive GDP-bound Ras is removed during washing steps. The bound active Ras is detected with a Ras specific antibody. The degree of Ras activation is determined by comparing readings from activated cell lysates versus non-activated cell lysates. Inactivation of Ras is generally achieved in tissue culture by a serum starvation step (see kit datasheet for more information).
The kit contains sufficient reagents to perform 96 Ras activation assays. Since the Ras-GTP affinity wells are supplied as strips and the strips can be broken into smaller pieces, each kit can be used for anywhere from one to multiple assays. The following components are included in the kit:
Figure 1. Ras activation by EGF measured by G-LISA™. HeLa cells were serum starved (SS) for 24 h and treated with EGF (100 ng/ml for 2 min). 25, 12.5, 5, 1.25 µg of cell lysates were subjected to the G-LISA™ assay. Absorbance was read at 490 nm. Data are background subtracted
Cdc42 G-LISA™ Activation Assay, colorimetric format (Cat.# BK127)
Rac1 G-LISA™ Activation Assay, luminescence format (Cat.# BK126)
G-LISA Rac 1,2,3 Activation Assay Biochem Kit (colorimetric format (Cat.# BK125)
RhoA G-LISA™ Activation Assay, colorimetric format (Cat.# BK124)
RhoA G-LISA™ Activation Assay, luminescence format (Cat.# BK121)
Wang, X., Yao, Y. & Gao, J. Sevoflurane inhibits growth factor-induced angiogenesis through suppressing Rac1/paxillin/FAK and Ras/Akt/mTOR. Futur. Oncol. 16, 1619–1627 (2020).
Kim, J. H. et al. Rational design of small molecule RHOA inhibitors for gastric cancer. Pharmacogenomics J. 20, 601–612 (2020).
Chen, G. P., Zhang, X. Q., Wu, T., Han, J. & Ye, D. Inhibition of farnesyl pyrophosphate synthase attenuates high glucose-induced vascular smooth muscle cells proliferation. Mol. Med. Rep. 15, 3153–3160 (2017).
Lu, H. et al. Research paper resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. Oncotarget 11, 265–281 (2020).
Casique-Aguirre, D. et al. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer 06 Biological Sciences 0601 Biochemistry and Cell Biology. BMC Cancer 18, 1–16 (2018).
Li, Q. fen, Decker-Rockefeller, B., Bajaj, A. & Pumiglia, K. Activation of Ras in the Vascular Endothelium Induces Brain Vascular Malformations and Hemorrhagic Stroke. Cell Rep. 24, 2869–2882 (2018).
Zhao, T. et al. Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK/RhoA-Mediated mTORC1/NF-κB and ERK1/2 Pathways. Int. J. Mol. Sci. 19, 1994 (2018).
S.-J. Lee et al. 2013. Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and krüppel-like factor 5. J. Biol. Chem. 288, 25244-25253.
L.D. Camargo et al. 2013. Endo-PDI is required for TNFα-induced angiogenesis. Free Radic. Biol. Med. 65, 1398-1407.
Gil-Henn et al. 2012. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene. doi:10.1038/onc.2012.284.